SUL was also only partially effective in this regard confirming our earlier observations with the specific COX-2 inhibitor, celecoxib which showed partial efficacy both in a murine model of sporadic BCCs and in patients with NBCCS [59]. Here, PTGS2 is linked to nevoid basal cell carcinoma syndrome.